IRIS UniCatt

Nero, Camilla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.538
AS - Asia 2.245
EU - Europa 1.813
SA - Sud America 459
Continente sconosciuto - Info sul continente non disponibili 175
AF - Africa 56
OC - Oceania 7
Totale 8.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.399
SG - Singapore 1.003
IT - Italia 657
CN - Cina 458
BR - Brasile 360
DE - Germania 245
SE - Svezia 240
VN - Vietnam 225
FR - Francia 137
HK - Hong Kong 127
IN - India 114
GB - Regno Unito 104
IE - Irlanda 85
FI - Finlandia 79
ID - Indonesia 65
JP - Giappone 61
UA - Ucraina 60
CA - Canada 56
NL - Olanda 50
RU - Federazione Russa 38
BD - Bangladesh 36
MX - Messico 36
AR - Argentina 31
KR - Corea 31
AT - Austria 21
PL - Polonia 21
BE - Belgio 19
IQ - Iraq 19
EC - Ecuador 16
ES - Italia 16
TR - Turchia 15
PH - Filippine 14
ZA - Sudafrica 14
IR - Iran 11
MA - Marocco 11
CL - Cile 10
CO - Colombia 10
PK - Pakistan 10
VE - Venezuela 10
HN - Honduras 9
JM - Giamaica 8
SA - Arabia Saudita 8
PE - Perù 7
PY - Paraguay 7
UZ - Uzbekistan 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 6
IL - Israele 6
JO - Giordania 6
KG - Kirghizistan 5
MY - Malesia 5
NI - Nicaragua 5
PT - Portogallo 5
CH - Svizzera 4
KE - Kenya 4
KZ - Kazakistan 4
LT - Lituania 4
NG - Nigeria 4
RO - Romania 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GT - Guatemala 3
HU - Ungheria 3
LB - Libano 3
NZ - Nuova Zelanda 3
SC - Seychelles 3
TN - Tunisia 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
AW - Aruba 2
BO - Bolivia 2
BZ - Belize 2
DZ - Algeria 2
GF - Guiana Francese 2
HR - Croazia 2
MD - Moldavia 2
MN - Mongolia 2
PR - Porto Rico 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
DM - Dominica 1
GD - Grenada 1
GE - Georgia 1
GI - Gibilterra 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
Totale 8.110
Salva come PNG Salva come JPEG
Città #
Singapore 581
San Jose 416
Ashburn 379
Chandler 272
Rome 238
Hong Kong 115
Beijing 108
New York 105
Los Angeles 86
Dublin 80
Ho Chi Minh City 71
Milan 70
Hefei 68
Hanoi 63
The Dalles 60
Hyderabad 57
Tokyo 56
Ann Arbor 54
Jakarta 53
Lauterbourg 52
Frankfurt am Main 42
Columbus 41
Dallas 41
Munich 41
St Louis 41
Helsinki 40
San Mateo 40
Santa Clara 39
Council Bluffs 35
Boardman 34
São Paulo 34
Boston 33
Jacksonville 31
Wilmington 30
Atlanta 28
Bar Harbor 28
Nanjing 23
Orem 23
Phoenix 23
Seoul 23
Moscow 22
Buffalo 21
Princeton 21
Brooklyn 19
Cattolica 19
Chicago 19
Kent 19
Marseille 18
Dearborn 17
Nuremberg 16
Rio de Janeiro 16
Vienna 16
Bari 15
Houston 15
London 15
Montreal 15
Brussels 14
Toronto 14
Turku 14
Warsaw 14
Amsterdam 13
Lappeenranta 13
Mexico City 13
North Bergen 13
Paris 12
Stockholm 12
Bexley 11
Denver 11
Fairfield 11
Lawrence 11
Nürnberg 11
Seattle 11
Shanghai 11
Johannesburg 10
Washington 10
Bologna 9
Leawood 9
Woodbridge 9
Baghdad 8
Brasília 8
Düsseldorf 8
Naples 8
Poplar 8
Redwood City 8
San Francisco 8
Bremen 7
Chennai 7
Da Nang 7
Newark 7
Vancouver 7
Abidjan 6
Amman 6
Campinas 6
Dhaka 6
Fortaleza 6
Guangzhou 6
Madrid 6
Memphis 6
Querétaro 6
Quito 6
Totale 4.344
Salva come PNG Salva come JPEG
Nome #
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 351
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 273
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 216
Patient-derived organoids in renal cell carcinoma: A review of methodologies and applications 196
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. 186
Privacy in Italian Clinical Reports: A NLP-Based Anonymization Approach 183
A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment 180
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids 165
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 156
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience 156
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 152
Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer 150
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 149
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 146
Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY) 145
Advanced and recurrent endometrial cancer: State of the art and future perspectives 145
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 141
Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer 141
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes 137
Targeting the hallmarks of ovarian cancer: The big picture 136
Pd-l1 expression on circulating tumour-derived microvesicles as a complementary tool for stratification of high-grade serous ovarian cancer patients 136
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center 131
Radiomics analysis of ultrasound images to discriminate between benign and malignant adnexal masses with solid morphology on ultrasound 131
A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study 130
Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study 130
Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer 127
One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer 127
Laparoscopic Management of a Small Bowel Recurrence of Endometrial Cancer 126
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 125
Recent progress in the use of pharmacotherapy for endometrial cancer 123
PARP Inhibitors Resistance: Mechanisms and Perspectives 123
Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience 122
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 119
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 118
Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications 117
Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: Prognostic role and clinical considerations 115
Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience 113
Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study 108
Sentinel-node biopsy in early stage ovarian cancer: a prospective multicentre study (SELLY) 108
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 108
Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study) 104
Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma 102
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 99
Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye 97
Newly diagnosed ovarian cancer: Which first-line treatment? 96
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 95
Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety 95
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres 91
Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY) 91
L1CAM Expression in Microcystic, Elongated, and Fragmented (MELF) Glands Predicts Lymph Node Involvement in Endometrial Carcinoma 89
Radiomics and Radiogenomics of Ovarian Cancer: Implications for Treatment Monitoring and Clinical Management 88
Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and Technique 84
Electronic nose-based volatile organic compound profiling in gynecologic oncology: current evidence and diagnostic accuracy 79
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 78
Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors 76
Management of stage III and IVa uterine cancer 75
Minilaparoscopic Aortic Lymphadenectomy 73
Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy 71
Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations 66
Image-guided real-time optical biopsy in oncologic surgery: a systematic review of the role of confocal microscopy in the era of digital surgery 56
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer 54
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 50
Circulating tumor DNA in endometrial cancer: clinical significance and implications 46
Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers 35
Developing and validating ultrasound-based machine-learning models incorporating radiomics features to predict malignancy in adnexal masses 33
Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis 32
A review of reviews of the prevalence of molecular biomarkers in vulvar cancer and their implications for prognosis refinement and treatment strategies 32
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib 25
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions 24
Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy 21
Unraveling Tumor Heterogeneity in Gynecological Cancer Using a Radiogenomics Approach 19
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC 17
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer 15
Focal lymphovascular space invasion: Friend or foe? A large retrospective analysis on stage I endometrioid endometrial carcinomas 15
A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease 14
Engineering ovarian tissue via biofabrication and 3D bioprinting: Challenges and emerging perspectives 13
Prediction Of Homologous Recombination Deficiency (HRD) From H&E Whole Slide Images Using Attention-Based Multiple Instance Learning In Ovarian Cancer 13
Correction to: Uterine cellular leiomyoma with a novel HMGA2::PLCZ1 fusion and aberrant cyclin D1 expression: expanding the molecular spectrum and highlighting a diagnostic pitfall (Virchows Archiv, (2026), 10.1007/s00428-025-04387-w) 11
Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers 10
Comprehensive genomic profiling and clinico-pathologic characterization of primary ovarian leiomyosarcoma 10
A comparative analysis of tumor markers reveals EDA fibronectin as a promising target in high-grade serous ovarian cancer 9
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 9
Ovarian cancer treatments strategy: Focus on parp inhibitors and immune check point inhibitors 9
Incidence and impact of low-volume lymph node metastasis in apparent early-stage ovarian cancer: MICR-OVARY study 9
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 8
Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data 8
Integration of PARP-inhibitors in ovarian cancer therapy 8
ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study 8
Prediction of germline BRCA 1/2 genes pathogenetic variants from ultrasound images of healthy ovaries: Radiogenomics as an innovative tool to prevent BRCA-related cancers (PROBE II) 8
Varan: a tool for managing mutational data and creating cancer studies in cBioPortal 7
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review 6
Key issues in diagnostic accuracy of sentinel lymph node biopsy in early-stage ovarian cancer: systematic review and meta-analysis 6
Immunotherapy in gynecological cancers 6
Uterine cellular leiomyoma with a novel HMGA2::PLCZ1 fusion and aberrant cyclin D1 expression: expanding the molecular spectrum and highlighting a diagnostic pitfall 6
Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how 5
Identification of a False-positive Multiplex Ligation-dependent Probe Amplification Result in BRCA1 Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay 5
PTEN and gynecological cancers 5
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer 5
BRCA2 and genetic mutations in prostate cancer: an updated practical guide on “when and how” testing across international guidelines 5
Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study 5
Totale 8.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.959
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.959
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022300 0 13 4 24 18 5 15 55 15 27 49 75
2022/2023737 93 96 52 115 37 91 34 53 74 16 32 44
2023/2024523 12 116 23 47 26 57 43 33 5 30 65 66
2024/20251.350 39 28 96 60 91 63 63 50 153 168 311 228
2025/20263.716 391 225 224 420 562 197 561 198 261 266 267 144
2026/20271.138 236 902 0 0 0 0 0 0 0 0 0 0
Totale 8.293